Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma.

Cell Death Differ 2019 Jul 25;26(7):1267-1282. Epub 2018 Sep 25.

IRCCS, Regina Elena National Cancer Institute, Rome, Italy.

Drug resistance imposes severe limitations to the efficacy of targeted therapy in BRAF-mutated metastatic melanoma. Although this issue has been mitigated by the development of combination therapies with BRAF plus MEK inhibitors, drug resistance inevitably occurs with time and results in clinical recurrences and untreatable disease. Hence, there is strong need of developing new combination therapies and non-invasive diagnostics for the early identification of drug-resistant patients. We report here that the development of drug resistance to BRAFi is dominated by a dynamic deregulation of a large population of miRNAs, leading to the alteration of cell intrinsic proliferation and survival pathways, as well as of proinflammatory and proangiogenic cues, where a prominent role is played by the miR-199b-5p/VEGF axis. Significant alterations of miRNA expression levels are detectable in tumor biopsies and plasma from patients after disease recurrence. Targeting these alterations blunts the development of drug resistance.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41418-018-0205-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748102PMC
July 2019
45 Reads
8.184 Impact Factor

Publication Analysis

Top Keywords

drug resistance
20
development drug
12
combination therapies
8
resistance
5
drug
5
developing combination
4
disease strong
4
strong developing
4
axis alterations
4
therapies non-invasive
4
early identification
4
played mir-199b-5p/vegf
4
diagnostics early
4
mir-199b-5p/vegf axis
4
non-invasive diagnostics
4
alterations mirna
4
identification drug-resistant
4
expression levels
4
occurs time
4
survival pathways
4

References

(Supplied by CrossRef)

C Franklin et al.
Eur J Surg Oncol 2017

PA Ascierto et al.
J Transl Med 2012

AM Menzies et al.
Lancet Oncol 2014

J Larkin et al.
N Engl J Med 2014

C Robert et al.
N Engl J Med 2015

G Moriceau et al.
Cancer Cell 2015

G Zhang et al.
J Clin Invest 2016

H Shi et al.
Cancer Discov 2014

A Roesch et al.
Oncogene 2015

L Fattore et al.
J Transl Med 2013

L Fattore et al.
Oncotarget 2015

Similar Publications